Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies.

52W Range

30thpctl

Volume

2.47×avg

Market Cap

230.01MUSD

P/E Ratio

-11.8TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Greenwich LifeSciences, Inc.

GLSINASDAQ Capital Market·USD·Closed

Greenwich LifeSciences, Inc.

GLSINASDAQ·USD·Closed

$15.67

−16.34%

$15.67

−$3.06 (16.34%)

52W Range

30thpctl

Volume

2.47×avg

Mkt Cap

230.01MUSD

P/E

-11.8TTM

Div Yield

–ann

GLSI: Greenwich LifeSciences, Inc. Stock Analysis | finqOS